Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22035529 | 0.77 | KDM5B (0.31) | KDM5A | |
| SCHEMBL10049703 | 0.75 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL9273442 | 0.73 | KDM5A (0.41) | KDM5AKDM4EALDH1A1 | |
| SCHEMBL16002393 | 0.70 | KDM5A (0.32) | KDM5A | |
| SCHEMBL9345587 | 0.68 | GAA (0.31) | KDM4EALDH1A1 | |
| SCHEMBL9345546 | 0.68 | GAA (0.31) | KDM4EALDH1A1 | |
| SCHEMBL21957413 | 0.67 | NOX4 (0.31) | — | |
| SCHEMBL12926006 | 0.66 | KDM5A (0.34) | KDM5A | |
| SCHEMBL9215563 | 0.65 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22017507 | 0.65 | KDM4E (0.40) | KDM5AKDM4EALDH1A1SMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM5A 2386/4885KDM4E 2522/4885ALDH1A1 476/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM5A 2386/4885KDM4E 2522/4885ALDH1A1 476/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KDM5A 2386/4885KDM4E 2522/4885ALDH1A1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.